Drugs by condition
Drugs approved for hereditary angioedema
Last checked: Nov 20, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations
Brand-name drugs approved
8
Still marketed, NDA or BLA
Drug classes
2
Novel drugs
7
New molecular entities and new biologics
In development
5
Investigational drugs in Phase 2 or 3
Newest approvals
The most recently first-approved brand-name drugs for hereditary angioedema.
- Orladeyo (Berotralstat Dihydrochloride) · Biocryst Priority reviewOrphanDec 11, 2025
- Dawnzera (Autoinjector) (Donidalorsen Sodium) · Ionis Pharms INC NovelOrphanAug 21, 2025
- Ekterly (Sebetralstat) · Kalvista NovelOrphanJul 3, 2025
- Andembry (Garadacimab-Gxii) · Csl Behring LLC NovelOrphanJun 16, 2025
- Orladeyo (Berotralstat Dihydrochloride) · Biocryst NovelOrphanDec 3, 2020
All approved drugs for hereditary angioedema, by class
Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 9 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.
Plasma Kallikrein Inhibitor (3)
Class not listed in FDA's data (5)
- Dawnzera (Autoinjector) Donidalorsen Sodium · Ionis Pharms INC · 2025
- Andembry Garadacimab-Gxii · Csl Behring LLC · 2025
- Orladeyo Berotralstat Dihydrochloride · Biocryst · 2020
- Firazyr Icatibant Acetate · Takeda Pharms USA · 2011
- Orladeyo Berotralstat Dihydrochloride · Biocryst · 2025
Drugs in development for hereditary angioedema
Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.
- siRNAADX-038, ADX-324Phase 37 trials
ADARx Pharmaceuticals, Inc. · Hereditary Angioedema, HAE, Hereditary Angioedema - Type 1
- DeucrictibantPHVS416, PHA121Phase 35 trials
Pharvaris Netherlands B.V. · Hereditary Angioedema (HAE), Hereditary Angioedema, Hereditary Angioedema Type I
- KVD900Phase 33 trials
KalVista Pharmaceuticals, Ltd. · Hereditary Angioedema
- NTLA-2002Phase 31 trial
Intellia Therapeutics · Hereditary Angioedema
- BW-20805Phase 21 trial
Shanghai Argo Biopharmaceutical Co., Ltd. · Hereditary Angioedema (HAE)
More on hereditary angioedema: recruiting trials · published research
Related in rare and genetic disease: Transthyretin amyloidosis · Fabry disease · Gaucher disease · Pompe disease · Phenylketonuria (PKU) · Achondroplasia
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.